ESPOO, Finland, June 29, 2016 -- Technology, engineering and project management company Neste Jacobs has worked on an assignment to prepare conceptual and basic design for Asia's largest human blood plasma fractionation plant project.
These phases of the project are now successfully completed to enable the implementation of the project by Sichuan Yuanda Shuyang Pharmaceutical Company.
Neste Jacobs has accumulated vast experience in human plasma fractionation over the last 40 years and the company has in-depth understanding of plasma technologies, production processes, operational aspects and cost levels required for a fully functional human plasma fractionation plant. This highly regulated biopharmaceutical sector sets high standards for the design and operation of the facility. Product safety, regulatory compliance, traceability and robust operability must be built-in during all design steps starting from conceptual and basic design now completed by Neste Jacobs.
"This project demonstrates that we are the world's leading expert in this very demanding bioindustry field", says Neste Jacobs CEO, Jarmo Suominen. "We have thorough understanding of various blood plasma technologies and a comprehensive network of partnerships in this field taking us way beyond our competition."
The plant now goes to the implementation phase, being built in China. "During the conceptual and basic phases of this project we have greatly contributed to our customer quality and functionality of the plant.
Our approach integrates technology, concepts and process knowledge within the automated operations and constructability. This way our customers can be confident about the functionality of the as such complex plasma fractionation plant", says Neste Jacobs Bioindustries Sales Director, Kari Kaskes. "We are without doubt a number one company in front line development of global bioindustries."
Read more about Neste Jacobs' Biopharma expertise at http://www.nestejacobs.com/industries/biopharma/
For more information, please contact:
Jarmo Suominen, CEO, Neste Jacobs Oy, tel. +358 50 458 3399
Kari Kaskes, Sales Director, Bioindustries, Neste Jacobs Oy, tel. + 358 50 458 9603
Neste Jacobs is a preferred solution provider of high-quality technology, engineering and project services for a wide range of industries in the fields of oil and gas, petrochemicals, chemicals, biorefining, biochemicals, biopharma and industrial infrastructure. We have 60 years of experience in technology development and industrial investment projects as well as maintenance and performance improvement in Europe, North and South America, Asia and the Middle East. In addition to our home market Nordic countries we are looking to grow in the global expanding markets. We employ 1300 professionals globally. www.nestejacobs.com
HUG#2023616


Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Instagram Outage Disrupts Thousands of U.S. Users
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



